We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Adjunctive laser-stimulated stem-cells therapy to primary reperfusion in acute myocardial infarction in humans: Safety and feasibility study.
- Authors
Elbaz‐Greener, Gabby; Sud, Maneesh; Tzuman, Oran; Leitman, Marina; Vered, Zvi; Ben‐Dov, Nissan; Oron, Uri; Blatt, Alex; Elbaz-Greener, Gabby; Ben-Dov, Nissan
- Abstract
<bold>Background: </bold>Low-level laser therapy (LLLT) has photobiostimulatory effects on stem cells and may offer cardioprotection. This cell-based therapy may compliment primary percutaneous coronary intervention (PPCI) in patients with ST-segment elevation myocardial infarction (STEMI).<bold>Objective: </bold>In this randomized control trial, our primary objective was to determine the safety and feasibility of LLLT application to the bone marrow in patients with STEMI undergoing PPCI.<bold>Methods: </bold>We randomly assigned patients undergoing PPCI to LLLT or non-laser therapy (NLT). In the LLLT group, 100 s of laser therapy was applied to the tibia bone prior to PPCI, as well as 24 and 72 h post-PPCI. In the control group, the power source was turned off. The primary outcome was the difference in door-to-balloon (D2B) time, and additional outcomes included differences in circulating cell counts, cardiac enzymes, and left-ventricular ejection fraction (LVEF) at pre-specified intervals post-PPCI.<bold>Results: </bold>Twenty-four patients were randomized to LLLT (N = 12) or NLT (N = 12). No adverse effects of the treatment were detected. The D2B time was not significantly different between the groups (41 ± 8 vs 48 ± 1 min; P = 0.73). Creatinine Phosphokinase area under the curve, was lower after LLLT (22 ± 10) compared to NLT (49 ± 12), but this was not statistically significant (P = 0.08). Troponin-T was significantly lower after LLLT (2.7 ± 1.4 ng/mL) in comparison to NLT (5.2 ± 1.8 ng/mL. P < 0.05). At 9 months, LVEF improved in both groups without a significant difference between LLLT (55 ± 9%) and NLT (52 ± 9%; P = 0.90).<bold>Conclusion: </bold>LLLT is a safe and feasible adjunctive cell-based therapy to PPCI that may benefit ischemic myocardium.
- Subjects
STEM cells; MYOCARDIAL infarction; CORONARY disease; BONE marrow; MESENCHYMAL stem cells
- Publication
Journal of Interventional Cardiology, 2018, Vol 31, Issue 6, p711
- ISSN
0896-4327
- Publication type
journal article
- DOI
10.1111/joic.12539